SCHEMBL5310758

SCHEMBL5310758

Cc1cc(Nc2c(C)cccc2C(=O)O)n(C)n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.46
POLB P06746 2/20 0.44
KDM4E B2RXH2 3/20 0.44
ALDH1A1 P00352 1/20 0.44
HPGD P15428 1/20 0.44
HSD17B10 Q99714 1/20 0.44
ACLY P53396 1/20 0.43
ENPP3 O14638 1/20 0.43
ALPL P05186 1/20 0.43
XIAP P98170 1/20 0.43
GFER P55789 2/20 0.42
KMT2A Q03164 4/20 0.42
MEN1 O00255 3/20 0.42
FTO Q9C0B1 1/20 0.41
MAPT P10636 1/20 0.41
AKR1B10 O60218 1/20 0.40
TRPA1 O75762 1/20 0.40
ABCB11 O95342 1/20 0.40
DHFR P00374 1/20 0.40
LMNA P02545 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5005305 0.84 TAS2R14 (0.46) SMN1; SMN2KDM4EALDH1A1GFERKMT2A
SCHEMBL1819141 0.83 GFER (0.58) SMN1; SMN2ALDH1A1HPGDGFERKMT2A
SCHEMBL5305949 0.83 TSHR (0.49) SMN1; SMN2POLBKDM4EALDH1A1KMT2A
SCHEMBL1815234 0.82 LMNA (0.50) SMN1; SMN2POLBALDH1A1HPGDENPP3
SCHEMBL5253749 0.81 GFER (0.61) SMN1; SMN2ALDH1A1HPGDGFERKMT2A
SCHEMBL1811819 0.80 KMT2A (0.46) SMN1; SMN2POLBKDM4EALDH1A1HPGD
SCHEMBL1810794 0.79 GFER (0.44) SMN1; SMN2POLBALDH1A1HPGDACLY
SCHEMBL1814089 0.78 MAPT (0.44) SMN1; SMN2POLBKDM4EALDH1A1HPGD
SCHEMBL1808088 0.78 KMT2A (0.48) POLBKDM4EALDH1A1GFERKMT2A
SCHEMBL13869002 0.77 LMNA (0.56) SMN1; SMN2ALDH1A1KMT2AMEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070253957-A1 Substituted N-Aryl-1H-Pyrazolo[3,4-B]Quinolin-4-Amines and Analogs as Activators of Caspases and Inducers of Apoptosis CYTOVIA, INC. (US) 2007-11-01 US disclosed
EP-1807426-A2 SUBSTITUTED N-ARYL-1H-PYRAZOLOÝ3,4-b¨QUINOLIN-4-AMINES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS Cytovia, Inc. (US) 2007-07-18 EP disclosed
WO-2006041900-A2 SUBSTITUTED N-ARYL-1H-PYRAZOLO[3,4-b]QUINOLIN-4-AMINES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS CYTOVIA, INC. (US) 2006-04-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070253957-A1 Substituted N-Aryl-1H-Pyrazolo[3,4-B]Quinolin-4-Amines and Analogs as Activators of Caspases and Inducers of Apoptosis CASP3, CASP7, CASP4 SMN1; SMN2 4292/4885POLB 2371/4885KDM4E 985/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.